These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39454411)

  • 1. Bortezomib induces cell apoptosis and increases the efficacy of αPD-1 in BCR::ABL T315I mutation CML by targeting UBE2Q1.
    Jiang F; Liu W; Zhou Y; Lin S; Zhang Q; Zhang W; Xue Y; Li C; Gao A; Shao M; Liao S; Ma T; Yu X
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113311. PubMed ID: 39454411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
    Ferrari-Amorotti G; Keeshan K; Zattoni M; Guerzoni C; Iotti G; Cattelani S; Donato NJ; Calabretta B
    Blood; 2006 Aug; 108(4):1353-62. PubMed ID: 16670262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph
    Peter B; Eisenwort G; Sadovnik I; Bauer K; Willmann M; Rülicke T; Berger D; Stefanzl G; Greiner G; Hoermann G; Keller A; Wolf D; Čulen M; Winter GE; Hoffmann T; Schiefer AI; Sperr WR; Zuber J; Mayer J; Valent P
    Am J Hematol; 2022 Sep; 97(9):1215-1225. PubMed ID: 35794848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
    Coluccia AM; Vacca A; Duñach M; Mologni L; Redaelli S; Bustos VH; Benati D; Pinna LA; Gambacorti-Passerini C
    EMBO J; 2007 Mar; 26(5):1456-66. PubMed ID: 17318191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.
    He N; Li G; Liu J; Liu W; Tian R; Ma D
    Front Immunol; 2024; 15():1452035. PubMed ID: 39635534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy.
    Decroos A; Meddour S; Demoy M; Piccirilli N; Rousselot P; Nicolini FE; Ragot S; Gombert JM; Herbelin A; Barbarin A; Cayssials E
    Front Immunol; 2024; 15():1473139. PubMed ID: 39620210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India.
    Hazarika G; Kalita MJ; Das PP; Kalita S; Dutta K; Lahkar L; Rajkonwar A; Idris MG; Khamo V; Kusre G; Medhi S
    Biochem Genet; 2024 Dec; 62(6):4804-4816. PubMed ID: 38363412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanism of Tongfu Lifei decoction inhibiting the programmed death-1/programmed death-ligand 1 signaling pathway in THP-1 cells by regulating microRNA-146a].
    Lyu B; Li L; Huang R; Zhou X; Han L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2024 Oct; 36(10):1038-1043. PubMed ID: 39586721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corosolic acid inhibits EMT in lung cancer cells by promoting YAP-mediated ferroptosis.
    Zhang C; Gao L; Zhang Y; Jin X; Wang M; Wang Q; Zhao W; Wu N; Zhang Y; Liu Y; Zhang Y; Ma L; Chen Y
    Phytomedicine; 2024 Dec; 135():156110. PubMed ID: 39369568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.
    Chang JS; Santhanam R; Trotta R; Neviani P; Eiring AM; Briercheck E; Ronchetti M; Roy DC; Calabretta B; Caligiuri MA; Perrotti D
    Blood; 2007 Aug; 110(3):994-1003. PubMed ID: 17475908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-Omic Analysis Reveals the Impact of Bortezomib in Hyperleukocytic Acute Myeloid Leukemia.
    Wu J; Li X; Xiong B; Yin W; Li R; Chen G; Ma L; Tong X; Liu X; Zhou F
    Cancer Med; 2024 Nov; 13(22):e70438. PubMed ID: 39584619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gambogic acid impairs the maintenance and therapeutic resistance of glioma stem cells by targeting B-cell-specific Moloney leukemia virus insert site 1.
    Sun T; Lin B; Sun Q; Zhang X; Wang T; Yang J; Liu X; Lu H; Lu N; Zhao K
    Phytomedicine; 2024 Dec; 135():156070. PubMed ID: 39326139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation.
    Quezada Meza CP; Salizzato V; Calistri E; Basso M; Zavatti M; Marmiroli S; Salvi M; Carter BZ; Donella-Deana A; Borgo C; Ruzzene M
    Int J Biol Macromol; 2024 Dec; 286():138305. PubMed ID: 39631575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells.
    Park DH; Bhojnagarwala PS; Liaw K; Bordoloi D; Tursi NJ; Zhao S; Binder ZA; O'Rourke D; Weiner DB
    J Immunother Cancer; 2024 Dec; 12(12):. PubMed ID: 39622583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
    Notari M; Neviani P; Santhanam R; Blaser BW; Chang JS; Galietta A; Willis AE; Roy DC; Caligiuri MA; Marcucci G; Perrotti D
    Blood; 2006 Mar; 107(6):2507-16. PubMed ID: 16293596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the PGAM5-CypD mitochondrial pathway in methylglyoxal-induced bone loss in diabetic osteoporosis.
    Jiang W; Ma X; Li B; Jiang T; Jiang H; Chen W; Gao J; Mao Y; Sun X; Ye Z; Zhao S; Huang S; Chen Y
    Bone; 2025 Jan; 190():117322. PubMed ID: 39510433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-antigen fusion protein vaccination induces protective immunity against
    Jia K; Zhang Y; Jiang M; Cui M; Wang J; Zhang J; Wang H; Zhao H; Li M; Zou Q; Zeng H
    Hum Vaccin Immunother; 2024 Dec; 20(1):2406065. PubMed ID: 39327639
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.